Active Ingredients: Isotretinoin
Address for correspondence: Jolanta D. This article has been cited by.
The study was followed by a 6-month observation period. The study was completed by 305 patients.
The average cumulative dose taken by patients was 38. Within a 6-month observation period, recurrences occurred in 50 16.
In, Lee et al. Sixty patients with moderate acne were qualified for the study.
The subjects were divided into 3 groups; patients in group A were given isotretinoin at the dose of 0. Efficacy, tolerability of the therapy and patient satisfaction were compared in all groups.
The therapy was followed by 1 year of observation.
The number of both inflammatory and non-inflammatory lesions was statistically significantly different in groups B and C as well as C and A whereas there were no statistically significant differences between groups A and B, which suggests that conventional therapy and therapy with low doses of isotretinoin are similarly effective.
Patient satisfaction scores were the highest in group B low doses of the drug, lower in group C intermittent therapy and the lowest in group A conventional therapy.
Adverse effects occurred most commonly in patients treated with the use of conventional method group A, compared to the groups treated with low doses of isotretinoin group B and intermittent method group C.
In, Rasi et al. The retrospective study was done on 140 patients 89 females, 51 males aged 18—40 years mean: 23.
The patient weight ranged from 50 to 110 kg mean: 65. Total clearance was achieved in 135 out of 140 patients treated with the use of this method 96.
The longest time of the therapy was 22 months, the shortest — 10 months. Within a 5-year observation period, recurrences were found in 11 7.
Mean time from treatment completion to a relapse was 17. Adverse effects during the therapy were mild and included: cheilitis 66.
Slightly elevated levels of liver enzymes and lipids in serum were found in 20 subjects. The study was done on 50 patients 25 females, 25 males; a half of the group received the above treatment regimen while the other half was given isotretinoin locally only.
The patients were divided into 2 age groups: group I consisted of patients aged 12—20 years while group II — those aged 21—35 years.
After a 3-month therapy, an improvement was observed in 90.
Four patients did not complete the therapy. Within a 2-year observation period after the treatment, recurrences occurred in 3.
Rademaker et al.